Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Source: View publication →
The addition of a fixed-dose combination of isosorbide dinitrate and hydralazine to standard medical therapy in Black patients with advanced heart failure significantly improved a primary composite score, enhanced quality of life, and reduced both all-cause mortality and heart failure hospitalizations.
Key Findings
Study Design
Study Limitations
Clinical Significance
The A-HeFT trial demonstrated that adding fixed-dose isosorbide dinitrate/hydralazine to standard neurohormonal blockade dramatically improves outcomes in self-identified Black patients with advanced heart failure. This profound survival benefit (43% mortality reduction) led to the FDA approval of BiDil specifically for this patient population, establishing it as a core component of guideline-directed medical therapy for African Americans with persistent symptomatic heart failure.
Historical Context
The rationale for A-HeFT stemmed from retrospective subgroup analyses of the earlier V-HeFT I and II trials, which suggested that African American patients experienced a unique survival benefit from the combination of isosorbide dinitrate and hydralazine, potentially due to underlying differences in nitric oxide bioavailability and oxidative stress. A-HeFT became a landmark—and widely debated—trial as the first prospective cardiovascular study designed to evaluate a therapy in a specific self-identified racial group, sparking significant scientific, ethical, and societal discussions regarding race-based medicine, pharmacogenomics, and the validity of using race as a proxy for genetic or physiological differences.
Guided Discussion
High-yield insights from every perspective
Hydralazine and isosorbide dinitrate (ISDN) target different aspects of hemodynamics. What are their respective primary sites of action (preload vs. afterload), and mechanistically, why are they given together rather than as monotherapy in heart failure?
Key Response
ISDN is primarily a venodilator that reduces preload by increasing venous capacitance, while hydralazine is a direct arterial vasodilator that reduces afterload. Together, they improve stroke volume and reduce cardiac work. Furthermore, hydralazine has potent antioxidant properties that mitigate the oxidative stress responsible for nitrate tolerance, allowing ISDN to remain effective during long-term therapy.
You are managing a 55-year-old African American male with NYHA class III HFrEF who is maximally titrated on standard guideline-directed medical therapy. You decide to add ISDN-hydralazine based on the A-HeFT trial. What are the most common adverse effects you should counsel him about, and what medication class is strictly contraindicated while he is on this therapy?
Key Response
The most common adverse effects requiring counseling are headache (driven by ISDN) and dizziness/hypotension. Hydralazine can also rarely cause drug-induced lupus erythematosus. Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) are strictly contraindicated due to the risk of profound, life-threatening hypotension when combined with nitrates.
The A-HeFT trial specifically enrolled self-identified Black patients. What is the proposed pathophysiological basis for the enhanced efficacy of ISDN-hydralazine in this demographic compared to others, and how does this relate to the concept of nitric oxide (NO) bioavailability?
Key Response
The working hypothesis is that Black patients with heart failure often have lower endothelial nitric oxide bioavailability and higher reactive oxygen species (ROS) burden compared to other demographics, leading to a NO-deficient state. ISDN acts as an exogenous NO donor, and hydralazine acts as an antioxidant to prevent NO degradation by ROS, specifically reversing this pathophysiologic deficit.
The introduction of BiDil (fixed-dose ISDN-hydralazine) sparked significant debate regarding race-based medicine, pill burden, and cost. How do you balance the robust mortality benefit seen in A-HeFT with the practical complexities of prescribing a therapy marketed for a specific racial group, especially when managing patients with mixed heritage or those struggling with polypharmacy?
Key Response
This addresses the real-world complexity of applying A-HeFT. Race is a social construct, making it biologically imprecise to limit life-saving therapy based strictly on self-identification. Attendings must often decide whether to trial it in non-Black patients who remain symptomatic despite optimal medical therapy. Additionally, the TID dosing of ISDN-hydralazine creates a high pill burden, meaning shared decision-making regarding adherence and financial toxicity is crucial for achieving the outcomes seen in the trial.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
A-HeFT utilized a novel primary composite scoring system that incorporated all-cause mortality, first hospitalization for heart failure, and change in quality of life. What are the methodological strengths and weaknesses of using this type of hierarchical composite endpoint rather than a traditional time-to-first-event analysis?
Key Response
A hierarchical composite score (similar to the Finkelstein-Schoenfeld method) increases statistical power and appropriately weights mortality over hospitalization and quality of life, solving the issue of standard time-to-first-event composites where a hospitalization could mask a later death. However, its primary weakness is that it complicates the clinical interpretation of the magnitude of benefit and makes direct cross-trial comparisons difficult.
The A-HeFT trial was terminated early by the Data and Safety Monitoring Board due to a significant mortality benefit. As an editor, how do you evaluate the potential for exaggerated effect sizes in trials stopped early for benefit, and how does the lack of a non-Black comparator arm impact the external validity and editorial framing of the findings?
Key Response
Trials stopped early for benefit are susceptible to the 'winner's curse,' often overestimating the true treatment effect due to random high fluctuations at the time of interim analysis. Furthermore, restricting the trial exclusively to Black patients removes the ability to prospectively compare the effect size against other groups, leaving it ambiguous whether the therapy is uniquely effective in this population or simply effective across the board but only tested in one group.
Based on the A-HeFT trial and subsequent data, how do the current ACC/AHA/HFSA guidelines recommend the use of ISDN-hydralazine in HFrEF? Specifically, what is the Class of Recommendation for self-identified African American patients, and in what alternative clinical scenario is this combination recommended for non-African American patients?
Key Response
Current ACC/AHA/HFSA guidelines give a Class 1 recommendation for adding ISDN-hydralazine to optimal medical therapy in self-identified African American patients with NYHA class III-IV HFrEF to reduce morbidity and mortality. Additionally, it holds a Class 2a/2b recommendation for any patient (regardless of race) with current or prior symptomatic HFrEF who cannot tolerate an ACEi, ARB, or ARNI due to severe renal impairment or hyperkalemia.
Clinical Landscape
Noteworthy Related Trials
V-HeFT I
Tested
Hydralazine and Isosorbide Dinitrate
Population
Men with chronic heart failure
Comparator
Placebo or Prazosin
Endpoint
All-cause mortality
V-HeFT II
Tested
Enalapril
Population
Men with chronic heart failure taking digoxin and diuretics
Comparator
Hydralazine and Isosorbide Dinitrate
Endpoint
All-cause mortality
SOLVD Treatment Trial
Tested
Enalapril
Population
Patients with heart failure and LVEF of 35 percent or less
Comparator
Placebo
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis